WO2007039122A2 - Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung - Google Patents

Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung Download PDF

Info

Publication number
WO2007039122A2
WO2007039122A2 PCT/EP2006/009178 EP2006009178W WO2007039122A2 WO 2007039122 A2 WO2007039122 A2 WO 2007039122A2 EP 2006009178 W EP2006009178 W EP 2006009178W WO 2007039122 A2 WO2007039122 A2 WO 2007039122A2
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pharmaceutical dosage
dosage form
release
form according
Prior art date
Application number
PCT/EP2006/009178
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2007039122A3 (de
Inventor
Klaus Benke
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37852804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007039122(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2008533890A priority Critical patent/JP5147703B2/ja
Priority to KR1020087010702A priority patent/KR101445398B1/ko
Priority to NZ567094A priority patent/NZ567094A/en
Priority to EP06792199A priority patent/EP1957048A2/de
Priority to BRPI0616874-4A priority patent/BRPI0616874A2/pt
Priority to US12/089,148 priority patent/US8586082B2/en
Priority to CN2006800455481A priority patent/CN101321517B/zh
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to AU2006299192A priority patent/AU2006299192B2/en
Priority to CA2624306A priority patent/CA2624306C/en
Publication of WO2007039122A2 publication Critical patent/WO2007039122A2/de
Publication of WO2007039122A3 publication Critical patent/WO2007039122A3/de
Priority to IL190618A priority patent/IL190618A0/en
Priority to CU20080052A priority patent/CU23808B7/es
Priority to NO20081982A priority patent/NO20081982L/no
Priority to HK09105035.7A priority patent/HK1127284A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to solid, orally administrable, 5-chloro-N - ( ⁇ (5-S) -2-oxo-3- [4- (3-oxo-4-methylphenyl) -phenyl] -1,3-oxazolidine -5-yl ⁇ -methyl) -2-thiophencarboxamide in pharmaceutical compositions containing amorphous form and / or thermodynamically metastable crystal modification with rapid release of active ingredient and process for their preparation, their use as medicaments, their use for prophylaxis, secondary prophylaxis and / or treatment of diseases and their use for the manufacture of a medicament for the prophylaxis, secondary prophylaxis and / or treatment of diseases.
  • 2-thio - - phencarboxamide (I) is a low molecular weight, orally administered inhibitor of the blood coagulation factor Xa, which can be used for the prophylaxis, secondary prophylaxis and / or treatment of various thromboembolic diseases (see WO-A 01/47919, the disclosure of which is hereby incorporated by reference
  • the active ingredient (I) when the active ingredient (I) is mentioned, all crystal modifications and the amorphous form of 5-chloro-N - ( ⁇ (5iS) -2-oxo-3- [4- (3-oxo 4-morpholinyl) -phenyl] -l, 3-oxazolidin-5-yl ⁇ -methyl) -2-thiophenecarbox
  • the physico-chemical and biological properties of the active compound (I) to be considered such as the relatively low water solubility (approximately 7 mg / L; 25 ° C) and the relatively high melting point of about 230 0 C of Active substance (S) in the crystal modification, in which the active ingredient (I) is obtained in the preparation according to the method described in WO 01/47919 (Chem. Abstr., 2001, / 3-5, 92625) under Example 44 and the following is referred to as crystal modification I.
  • WO 2005/060940 describes pharmaceutical administration forms which contain the active ingredient (I) in hydrophilized form. Preference is given to fast-release tablets which have a Q value (30 minutes) of 75% according to USP (United States Pharmacopeia) release method with apparatus 2 (paddle).
  • dosage forms containing active ingredient (I) in amorphous form and / or in the form of thermodynamically metastable crystal modifications have improved bioavailability.
  • the present invention relates to solid, orally administrable, rapid-release pharmaceutical dosage forms containing 5-chloro-N- ( ⁇ (55) -2-oxo-3- [4- (3- oxo-4-mo ⁇ holinyl) -phenyl] -l, 3-oxazolidin-5-yl ⁇ -methyl) -2-thiophenecarboxamide (I), characterized in that they contain active substance (I) in amorphous form and / or thermodynamically metastable Kristallmodif ⁇ kation and that 80% of the active ingredient (I) is released for a maximum of 2 hours according to the USP release method with apparatus 2 (paddle, 75 rpm). The further conditions of these in vitro release studies according to the USP release method are described in the experimental part (sink conditions). The amount of 80% active ingredient (I) to be released refers to the total amount of active ingredient (I) contained in the dosage form.
  • 80% of the active ingredient (I) is released in a period of a maximum of 1 hour according to USP release method with apparatus 2 (paddle, 75 rpm).
  • the active ingredient (I) can be present in the dosage forms according to the invention partially or completely in amorphous form and / or thermodynamically metastable Kristallmodif ⁇ kation.
  • the administration forms according to the invention preferably comprise active ingredient (I) in amorphous form and / or in the form of metastable crystal modifications in an amount based on: the total amount of active ingredient (I) present of at least 50%, particularly preferably more than 50%, in particular, at least 90%.
  • the active ingredient (I) in the dosage forms of the invention may be partially or completely contained in amorphous form.
  • the dosage forms according to the invention preferably contain active ingredient (I) in amorphous form in an amount, based on the total amount of active ingredient (I), of at least 50%, particularly preferably more than 50%, in particular at least 90%.
  • the partial or complete presence of the active ingredient (I) in amorphous form and / or in the form of one or more thermodynamically metastable crystal modifications in addition to a rapid release rate also increases the drug solubility.
  • the dosage forms of the invention contain active ingredient (I) in amorphous form and / or in the form of metastable crystal modifications preferably in an amount based on the contained Total amount of active ingredient (I), of at least 50%, more preferably more than 50%, especially at least 90%.
  • the term “supersaturation” in this context means that the inventive formulations compared to crystalline, micronized drug (I) in the Rristallmodtechnik I under the in vitro defined in the experimental part Release conditions under non-sink conditions at a dose of 20 mg of active ingredient (I) after one hour at least a factor of 1.5 higher release drug.
  • the dosage forms of the invention contain active ingredient (I) in a total amount of 20 mg and set a compared to 20 mg micronized crystalline active ingredient (I) in the crystal modification I at least the
  • the micronized active ingredient (I) under these conditions after one hour release of 40% (8 mg), so the formulations of the invention release values of at least 60% (12 mg).
  • the micronized active ingredient (I) has an average particle size X 50 -WeIt (50% proportion) of 1 to 8 microns and an X 90 - (90% proportion) of less than 20 microns.
  • the partial or complete presence of the active compound (I) in amorphous form in addition to a rapid release rate, also increases the drug solubility.
  • the dosage forms of the invention contain active ingredient (I) in amorphous form preferably in an amount, based on the total amount of active ingredient (I) contained, of at least .50. %, more preferably more than 50%, especially at least 90%.
  • the dosage forms of the invention contain active ingredient (I) in a total amount of 20 mg and set a compared to 20 mg micronized crystalline active ingredient (I) in the crystal modification I at least a factor of 1.5 higher amount of active ingredient (I) in a period of one hour according to the USP release method with apparatus 2 (paddle) free. If, for example, the micronised active substance (I) has a release of 40% (8 mg) after one hour under these conditions, the formulations according to the invention show release values of at least 60% (12 mg).
  • the micronized active ingredient (I) has a mean Particle size X 50 value (50% proportion) of 1 to 8 microns and an X 90 -WeIt (90% proportion) of less than 20 microns on.
  • the Lieremethode in which an active ingredient and optionally used adjuvant (s) such as polyvinylpyrrolidone are dissolved and then further processed, less well suited, since this only a limited solubility in pharmaceutically suitable organic solvents - such as acetone or ethanol and therefore must use disproportionately large amounts of solvent must be.
  • an active ingredient and optionally used adjuvant (s) such as polyvinylpyrrolidone are dissolved and then further processed, less well suited, since this only a limited solubility in pharmaceutically suitable organic solvents - such as acetone or ethanol and therefore must use disproportionately large amounts of solvent must be.
  • An exception is pure acetic acid as a suitable solvent for the crystalline active ingredient (I) - a suitable method of preparation is described in the experimental part.
  • the active ingredient (I) is preferably present in a concentration of 0.1 to 30%, particularly preferably 0.1 to 20%, in particular 5 to 15%, based on the total weight of the dissolved components, in the mixture present after the dissolving process.
  • the erfmdungswash preferred method for amorphization of the active ingredient (I) and for generating thermodynamically metastable crystal modifications or for stabilizing the amorphous state of the active ingredient (I) in the pharmaceutical preparations is the melting process in which an active ingredient together with or in one or more suitable excipients is melted.
  • ureas citric acid, stearic acid, sugars, sugar alcohols such as mannitol or xylitol and hydrophilic polymers such as polyethylene glycols (PEG), polyethylene oxides, polyoxyethylene-polyoxypropylene block copolymers and vinylpyrrolidone-vinyl acetate copolymers, hydroxypropylcellulose (HPC ), saturated polyglycolized glycerides (Gelucire, Gattefosse) or mixtures of these excipients.
  • PEG polyethylene glycols
  • HPC hydroxypropylcellulose
  • Gelucire Gattefosse
  • Preferred auxiliaries are polyethylene glycols, mixtures of polyethylene glycols and mixtures of one or more polyethylene glycols with one or more other suitable excipients, particularly preferably polyethylene glycols and mixtures of polyethylene glycols, in particular polyethylene glycols.
  • the active ingredient (I) is added to the molten adjuvant mixture and the temperature is increased until a clear melt is present or the active ingredient (I) and the excipient (s) are first mixed and then melted.
  • the melt After melting, the mixture is cooled and then comminuted, so that preferably a powder or granulate is present, which can also be referred to as a "solid solution.” Alternatively, the melt can be filled after comminution, for example, into capsules or as Sachet, optionally after admixing suitable pharmaceutical.
  • this melting process ensures that the active ingredient degradation during the melting process does not exceed pharmaceutically acceptable limits, which is a difficult one with a melting point of about 230 ° C. of the active ingredient (I) in the crystal modification I. Task, since in this high temperature range usually significant decomposition rates of the active ingredient and / or the excipients are to be expected.
  • the active ingredient (I) is present in the mixture present after the melting process preferably in a concentration of 0.1 to 30%, more preferably of 0.1 to 20%, in particular of 5 to 15%, based on the total mass of the melt.
  • melt extrusion process is particularly preferred for the preparation of active ingredient (I) in pharmaceutical forms containing amorphous form or metastable crystal modifications [Breitenbach, J., "Melt extrusion: From process to drug delivery technology”, European Journal of Pharmaceutics and Biopharmaceutics 54 (US Pat. Werbach, J., "Solid solutions by melt extrusion - an integrated manufacturing concept", Pharmacy in our time 29 (2000), 46-49].
  • the melt extrusion process for preparing the active ingredient (I) in amorphous form or in the form of metastable crystal modifications is preferably in the presence of a polymer such as polyvinylpyrrolidone (PVP), polyethylene glycol, polymethacrylate, polymethyl methacrylate, polyethylene oxide, polyoxyethylene-polyoxypropylene block copolymers, vinyl -pyrrolidone-vinyl acetate copolymers or a cellulose ether such as hydroxypropyl cellulose (HPC) or performed mixtures of various polymers.
  • PVP polyvinylpyrrolidone
  • HPC hydroxypropyl cellulose
  • HPC Hydroxypropylcellulose
  • PVP polyvinylpyrrolidone
  • HPC hydroxypropyl cellulose
  • PVP polyvinylpyrrolidone
  • the polymer content in the melt extrudate according to the invention is preferably at least 40% of the total mass of the melt extrudate.
  • the active ingredient (I) is present in the melt extrudate according to the invention preferably in a concentration of 0.1 to 20%, in particular of 5 to 15%, based on the total mass of the melt extrudate.
  • these pharmaceutically suitable substances are added according to the invention in a concentration of 0.2 to 40%, based on the total mass of the melt extrudate.
  • urea polymers such as polyethylene glycol, polymethacrylates, polymethyl methacrylates, polyethylene oxide, polyoxyethylene-polyoxypropylene block copolymers, vinylpyrrolidone-vinyl acetate copolymers, saturated polyglycolized glycerides (Gelucire, Gattefosse) or sugar alcohols such as erythritol, maltitol, mannitol, sorbitol and xylitol.
  • sugar alcohols are used.
  • the product obtained, for example, by the dissolution method, the melt or the melt extrusion method, active substance (I) in amorphous form or metastable crystal modification (s) containing product can be processed in different ways: It can, for example, be comminuted and administered as a powder or granules, optionally after filling as sachet or in capsules.
  • customary pharmaceutical auxiliaries can be added, for example fillers, flow regulators, adsorbents, wetting agents, flavors and dyes.
  • the product containing the active ingredient (I) in amorphous form or metastable crystal modifications can be further processed into tablet formulations.
  • it can be cut, ground and mixed with conventional tabletting excipients such as fillers and dry binders (for example cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, mannitol, maltitol, sorbitol, xylitol, lactose, dextrose, maltose, sucrose, glucose, fructose or maltodextrins), disintegrants / disintegrants (for example, carboxymethylcellulose, croscarmellose (cross-linked carboxymethylcellulose), crospovidone (cross-linked polyvinylpyrrolidone), L-HPC (low-substituted hydroxypropylcellulose), sodium carboxymethylstarch, potato starch sodium glycolate, partially hydrolyzed starch, wheat starch
  • Suitable materials for a sunscreen and / or lake are for example polymers such as polyvinyl alcohol, hydroxypropyl cellulose and / or hydroxypropylmethyl cellulose, optionally in combination with suitable plasticizers such as polyethylene glycol or polypropylene glycol and pigments such as titanium dioxide or iron oxides.
  • the tablets are preferably rapidly disintegrating tablets with a disintegration time of a maximum of 30 minutes.
  • Another object of the present invention is a process for the preparation of the tablet formulation according to the invention, wherein by means of the Lcaptivatemethode, preferably by means of the melting process, most preferably by means of melt extrusion, an active ingredient (I) in amorphous form or metastable crystal modification containing solid solution or Extrudate is prepared, which (s) then ground, mixed with other pharmaceutical excipients known in the art and filled into capsules or Sachet or mixed with other known in the art Tablettieragisstoffn (see above) and then preferably compressed by direct tableting into tablets, the final can be coated with a varnish.
  • active ingredient (I) is present in amorphous form.
  • multiparticulate dosage forms are understood as meaning those formulations which consist of a plurality of small particles, such as, for example, spherical granules (pellets) or minitablets The diameter of these particles is generally 0.5 to 3.0 mm
  • the cut and rounded extrudates or small-format tablets may optionally be varnished and filled into capsules or prepared as Sachet.
  • active ingredient (I) is present in amorphous form.
  • Another object of the present invention are pharmaceutical dosage forms, preferably capsules, sachets or tablets containing the multiparticulate dosage forms described above.
  • Another object of the present invention is a process for the preparation of multiparticulate pharmaceutical dosage forms according to the invention, wherein preferably by melt extrusion an active ingredient (I) in amorphous form and / or thermodynamically metastable crystal modification containing extrudate is obtained.
  • a pellet-shaped multiparticulate dosage form is prepared directly by cutting this extrudate strand and optionally subsequent rounding. The pellets thus obtained can then be coated with a varnish and filled into capsules or sachets.
  • active ingredient (I) is present in amorphous form.
  • the present invention further relates to medicaments containing a solid, orally administrable, rapidly releasable pharmaceutical preparation containing active ingredient (I) in amorphous form and / or thermodynamically metastable crystal modification (s).
  • active ingredient (I) is present in amorphous form.
  • Another object of the present invention is the use of the solid, orally administered pharmaceutical dosage form according to the invention with rapid release of active ingredient containing amorphous and / or thermodynamically metastable active ingredient (I) for the prophylaxis, secondary prophylaxis and / or treatment of diseases, in particular of arterial and / or venous thromboembolic Diseases such as myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive disease, pulmonary embolism or deep venous thrombosis.
  • active ingredient (I) is present in amorphous form.
  • Another object of the present invention is the use of the solid, orally administrable, the amorphous and / or thermodynamically metastable active ingredient (I) containing pharmaceutical dosage form with rapid release drug, for the manufacture of a medicament for the prophylaxis, secondary prophylaxis and / or treatment of diseases, in particular of arterial and / or venous thromboembolic disorders such as myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis following angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms, or deep venous thrombosis.
  • active ingredient (I) is present in amorphous form.
  • Another object of the present invention is the use of 5-chloro-N - ( ⁇ (5iS) -2-oxo-3- [4- (3-oxo-4-mo ⁇ holinyl) -phenyl] -l, 3-oxazolidin-5 -yl ⁇ -methyl) -2-thiophenecarboxamide (I) for the preparation of a solid, orally administrable pharmaceutical dosage form according to the invention with rapid release of active ingredient.
  • Another object of the present invention is a method for the prophylaxis, secondary prophylaxis and / or treatment of arterial and / or venous thromboembolic diseases by administering a solid, orally administrable, active ingredient (I) in amorphous form and / or thermodynamically metastable crystal modification containing pharmaceutical dosage form with faster drug release.
  • active ingredient (I) is present in amorphous form.
  • the in vitro release studies are performed according to USP release method with apparatus 2 (paddle) at a temperature of 37 0 C.
  • the speed of rotation of the stirrer is 75 rpm (revolutions per minute) in 900 ml of an acetate buffer solution of pH 4.5, which is prepared from 29.9 g sodium acetate trihydrate and 16.6 ml glacial acetic acid in 10 L water.
  • the investigations are carried out under sink or non-sink conditions.
  • Sink conditions The drug release rate is determined under sink conditions.
  • a surfactant preferably sodium lauryl sulfate
  • the solubility of the medium for the active ingredient (I) is optionally adjusted by the addition of surfactant, preferably sodium lauryl sulfate, so that it is higher by a factor of 3 to 10 than the saturation solubility of the drug dose to be tested.
  • Non-sink conditions The tests for checking the supersaturation (increase in solubility) are carried out without addition of a surfactant and with a dose of 20 mg of active substance (I) to be released.
  • the tablet formulation was tablet B described in WO 2005/060940 in the experimental section under point 5.1 with regard to composition and preparation, which was then subsequently lacquered with the following composition of the lacquer (in mg / tablet):
  • Polyethylene glycol is melted in a heatable reaction vessel (with stirrer and temperature probe). After reaching a temperature of about 210 0 C, the micronized active ingredient (I) is added and further heated. After reaching a temperature of 220-230 0 C, the clear Melt drained in sheets and these cooled using ⁇ on dry ice. After rasping the comminution takes place in an impact mill, so that a powdery product is formed.
  • example formulation 1 has a significantly increased solubility (supersaturation) in comparison with the micronized active ingredient (I) (Comparison 1.1). After 1 hour, a higher solubility by a factor of 2 can be detected.
  • Hydroxypropyl cellulose (type HPC-M, Nisso) 3900 g Xylitol 900 g 5250 g
  • Micronized drug (I), hydroxypropylcellulose and xylitol are mixed and processed in a twin-screw extruder (Leistritz Micro 18 PH) with a 2 mm diameter exit nozzle.
  • the mixture is extruded at a rate of about 1 kg / h and the following temperatures of the heating zones: 20 ° C. (zone 1), 100 ° C. (zone 2), 174 ° C. (zone 3) and 194 ° C. (zones A - 8 and nozzle exit).
  • the extrudate strand obtained is cut into approximately 1 mm pieces and then ground in an impact mill.
  • Example Formulation 2 In vitro release (non-sink conditions) of Example Formulation 2 (drug dose 20 mg, sieve fraction ⁇ 315 ⁇ m):
  • example formulation 2 has a significantly increased solubility (supersaturation) in comparison with the micronized active compound (I) (Comparison 1.1). After 1 hour, a higher solubility by a factor of 2.1 can be detected.
  • Micronized drug (I), polyvinylpyrrolidone and xylitol are mixed and processed in a twin-screw extruder (Leistritz Micro 18 PH) with a 2 mm diameter exit nozzle.
  • the mixture is extruded at a rate of about 1 kg / h and the following temperatures of the heating zones: 20 ° C. (zone 1), 100 ° C. (zone 2), 180 ° C. (zone 3) and 200 ° C. (zones 4 -8 and nozzle exit).
  • the extrudate strand obtained is cut into approximately 1 mm pieces and then ground in an impact mill.
  • example formulation 3 has a significantly increased solubility (supersaturation) compared to the micronized active ingredient (I) (Comparison 1.1). After 1 hour, the solubility is 2.4 times higher.
  • Tablets comprising active substance (I) in metastable crystal modification in the form of a PEG melt
  • composition for tablets containing 10 mg of active ingredient (I) (mg / tablet): Active ingredient (I) -PEG 6000 melt (see Example 1) 100 mg *
  • a drug (I) -PEG melt is prepared as described in Example 1. After sieving (0.63 mm), the other auxiliaries (see above table) are mixed in and this mixture is compressed on a tablet press into tablets in oblong format 17 ⁇ 7 mm with a flexural strength of about 40 N.
  • Example Formulation 4 In-vitro release (non-sink conditions) of Example Formulation 4 (drug dose 20 mg, 2 tablets / vessel):
  • example formulation 4 has a significantly increased solubility (supersaturation) in comparison with the micronized active ingredient (I) (Comparison 1.1). After 1 hour, a higher solubility by a factor of 2.1 can be detected.
  • composition for tablets containing 10 mg of active ingredient (I) (mg / tablet): Active ingredient (I> HPC extrudate (see Example 2) 1 17 mg *
  • An active compound (I) -HPC melt extrudate is prepared as described in Example 2 After sieving (0.4 mm), the other auxiliaries (see table above) are admixed and this mixture is spread on a tablet press into tablets in oblong format 17 ⁇ 7 mm with a bend. festigeit of about 40 N pressed.
  • example formulation 5 has a significantly increased solubility (supersaturation) compared to the micronized active ingredient (I) (Comparison 1.1). After 1 hour, a solubility which is higher by a factor of 2.5 is noticeable.
  • Active ingredient (I) micronized (MOD 1) 4.0 g polyvinylpyrrolidone 25 28.0 g
  • Glacial acetic acid pure acetic acid 140.0 g
  • active ingredient (I) is dissolved in glacial acetic acid at a temperature of about 90 - 100 0 C and the solvent is then distilled off under vacuum. The remaining mass is roughly crushed and transferred to a vacuum oven. In the vacuum drying is carried out for about 48 hours at a temperature of 100-120 0 C. The granules are ground in a mortar and sieved ( ⁇ 1 mm).
  • example formulation 6 has a significantly increased solubility (supersaturation) in comparison with the micronized active ingredient (I) (Comparison 1.1). After 1 hour, a higher solubility by a factor of 2 can be detected.
  • thermodynamically stable crystal modification I in the form of the micronized crystalline active substance in the thermodynamically stable crystal modification I (suspended in 0.5% aqueous methylhydroxyethylcellulose (trade name: Tylose MH 300))
  • Example formulation 1 containing active ingredient (I) in thermodynamically metastable crystal modification and example formulations 2 and 3 containing active ingredient (I) in amorphous form have a significantly improved bioavailability compared to the application of the crystalline micronized active ingredient in the thermodynamically stable crystal modification I (factor 3.2 for example formulation 1) Factor 3.5 for example formulation 2 and factor 3.7 for example formulation 3).
  • Example formulation 1 containing active ingredient (I) in thermodynamically metastable crystal modification has a significantly improved bioavailability compared to the application of the crystalline micronized active substance in the thermodynamically stable crystal modification I (factor 3.6).
  • Example formulation 4 containing active ingredient (I) in thermodynamically metastable crystal modification has in comparison to the comparative formulation 1.2 (tablet containing crystalline micronized drug (I) in the thermodynamically stable crystal modification I) improved bioavailability (factor about 1.5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/EP2006/009178 2005-10-04 2006-09-21 Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung WO2007039122A2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2624306A CA2624306C (en) 2005-10-04 2006-09-21 Solid pharmaceutical dosage forms which can be adminstered orally and have rapid release of active ingredient
CN2006800455481A CN101321517B (zh) 2005-10-04 2006-09-21 能够口服和活性成分快速释放的固体药物剂型
NZ567094A NZ567094A (en) 2005-10-04 2006-09-21 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
EP06792199A EP1957048A2 (de) 2005-10-04 2006-09-21 Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
AU2006299192A AU2006299192B2 (en) 2005-10-04 2006-09-21 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
US12/089,148 US8586082B2 (en) 2005-10-04 2006-09-21 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
KR1020087010702A KR101445398B1 (ko) 2005-10-04 2006-09-21 활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태
JP2008533890A JP5147703B2 (ja) 2005-10-04 2006-09-21 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態
BRPI0616874-4A BRPI0616874A2 (pt) 2005-10-04 2006-09-21 formas sólidas de apresentação farmacêutica de administração oral com liberação rápida de substáncia ativa
IL190618A IL190618A0 (en) 2005-10-04 2008-04-03 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
CU20080052A CU23808B7 (es) 2005-10-04 2008-04-04 Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
NO20081982A NO20081982L (no) 2005-10-04 2008-04-25 Faste, oralt administrerbare farmasoytiske doseringsformer med rask frigivelse av aktiv forbindelse
HK09105035.7A HK1127284A1 (en) 2005-10-04 2009-06-04 Solid orally administerable pharmaceutical dosage forms with rapid active principle release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005047561A DE102005047561A1 (de) 2005-10-04 2005-10-04 Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047561.2 2005-10-04

Publications (2)

Publication Number Publication Date
WO2007039122A2 true WO2007039122A2 (de) 2007-04-12
WO2007039122A3 WO2007039122A3 (de) 2007-10-11

Family

ID=37852804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009178 WO2007039122A2 (de) 2005-10-04 2006-09-21 Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung

Country Status (27)

Country Link
US (1) US8586082B2 (ko)
EP (1) EP1957048A2 (ko)
JP (1) JP5147703B2 (ko)
KR (1) KR101445398B1 (ko)
CN (1) CN101321517B (ko)
AR (1) AR056564A1 (ko)
AU (1) AU2006299192B2 (ko)
BR (1) BRPI0616874A2 (ko)
CA (1) CA2624306C (ko)
CR (1) CR9864A (ko)
CU (1) CU23808B7 (ko)
DE (1) DE102005047561A1 (ko)
DO (1) DOP2006000209A (ko)
EC (1) ECSP088339A (ko)
GT (1) GT200600445A (ko)
HK (1) HK1127284A1 (ko)
IL (1) IL190618A0 (ko)
MY (1) MY143351A (ko)
NZ (1) NZ567094A (ko)
PE (1) PE20070588A1 (ko)
RU (1) RU2440119C2 (ko)
SV (1) SV2009002857A (ko)
TW (1) TWI389691B (ko)
UA (1) UA90545C2 (ko)
UY (1) UY29835A1 (ko)
WO (1) WO2007039122A2 (ko)
ZA (1) ZA200802873B (ko)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003641A1 (en) 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
WO2010017948A2 (en) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
US7767702B2 (en) 2001-06-20 2010-08-03 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones for combinational therapy
WO2010140007A2 (en) * 2009-06-05 2010-12-09 Euro-Celtique S.A. Dosage form
WO2010146179A2 (en) 2009-06-18 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
WO2011042156A1 (en) 2009-10-06 2011-04-14 Ratiopharm Gmbh Pharmaceutical compositions comprising rivaroxaban
US7932278B2 (en) 2005-09-23 2011-04-26 Bayer Schering Pharma Aktiengesellschaft 2-aminoethoxyacetic acid derivatives and their use
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US8106192B2 (en) 2003-01-07 2012-01-31 Bayer Pharma Aktiengesellschaft Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US8129378B2 (en) 1999-12-24 2012-03-06 Bayer Pharma Aktiengesellschaft Substituted oxazolidinones and their use in the field of blood coagulation
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
WO2012080184A2 (de) 2010-12-15 2012-06-21 Bayer Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8586082B2 (en) 2005-10-04 2013-11-19 Bayer Intellectual Property Gmbh Solid orally administerable pharmaceutical dosage forms with rapid active principle release
US9402851B2 (en) 2003-11-27 2016-08-02 Bayer Intellectual Property Gmbh Process for the preparation of a solid, orally administrable pharmaceutical composition
US9539218B2 (en) 2005-01-31 2017-01-10 Bayer Intellectual Property Gmbh Prevention and treatment of thromboembolic disorders
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
WO2022199896A1 (en) 2021-03-24 2022-09-29 Pharmathen S.A. Pharmaceutical composition comprising rivaroxaban and method of preparation thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
WO2013022924A1 (en) 2011-08-08 2013-02-14 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations
EP2808011A1 (en) * 2013-05-29 2014-12-03 Sandoz Ag Process for the preparation of a pharmaceutical composition comprising Rivaroxaban
CN103550166A (zh) * 2013-10-31 2014-02-05 江苏阿尔法药业有限公司 一种利伐沙班口服微球制剂
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
KR102333463B1 (ko) * 2014-07-02 2021-12-03 한미약품 주식회사 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
CN104666262B (zh) * 2015-02-03 2017-09-15 山东新时代药业有限公司 一种利伐沙班片
JPWO2017175792A1 (ja) * 2016-04-06 2019-02-14 アステラス製薬株式会社 速溶出性三次元造形物、速溶出性三次元造形物用フィラメント及び速溶出性三次元造形物用材料
US20190336453A1 (en) * 2017-01-04 2019-11-07 BonAyu Lifesciences Private Limited Oral dispersible film composition
JP7305527B2 (ja) * 2018-11-30 2023-07-10 大原薬品工業株式会社 リバーロキサバンと嬌味剤を含有する固形製剤
US11073030B1 (en) * 2020-05-21 2021-07-27 Raytheon Technologies Corporation Airfoil attachment for gas turbine engines
JP2022140430A (ja) * 2021-03-10 2022-09-26 日本ジェネリック株式会社 リバーロキサバン含有錠剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060940A2 (de) * 2003-11-27 2005-07-07 Bayer Healthcare Ag Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung
WO2006072367A1 (de) * 2004-12-24 2006-07-13 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US629201A (en) * 1898-07-13 1899-07-18 Adolph Mueller Means for preventing sparking when and breaking electric circuits.
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ES8506659A1 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
CA1317594C (en) 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US5564571A (en) 1993-07-19 1996-10-15 Cembre S.P.A. Strip for electrical connectors
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
JPH10513446A (ja) 1995-02-03 1998-12-22 ファルマシア・アンド・アップジョン・カンパニー ヘテロ芳香族環置換フェニルオキサゾリジノン抗微生物剤
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE207487T1 (de) 1995-09-01 2001-11-15 Upjohn Co Phenyloxazolidinone mit einer c-c-bindung zu 4-8 gliedrigen heterocyclen
PT1019385E (pt) 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
HU225415B1 (en) 1996-07-15 2006-11-28 Sankyo Co Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
JPH10175816A (ja) * 1996-12-18 1998-06-30 Toray Dow Corning Silicone Co Ltd 化粧品原料、化粧品、および化粧品の製造方法
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
ATE293609T1 (de) 1997-05-30 2005-05-15 Upjohn Co Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität
AU729745B2 (en) 1997-07-11 2001-02-08 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
EP1030852B1 (en) 1997-11-12 2003-09-17 PHARMACIA & UPJOHN COMPANY Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
WO1999037630A1 (en) 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
SK11082000A3 (sk) 1998-01-27 2001-01-18 Aventis Pharmaceuticals Products Inc. Substituované oxoazaheterocyklické inhibítory faktora xa, farmaceutický prostriedok s ich obsahom a ich použitie
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
NZ508256A (en) 1998-05-18 2003-08-29 Upjohn Co Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
JP2003518117A (ja) 1999-12-21 2003-06-03 ファルマシア・アンド・アップジョン・カンパニー スルホキシミン官能基を有するオキサゾリジノンおよび抗微生物剤としてのその使用
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1413218A (zh) 1999-12-28 2003-04-23 味之素株式会社 天冬甜素衍生物的结晶
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
ES2307653T3 (es) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. Preparaciones que contienen nateglinida.
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
CN1819817A (zh) * 2003-07-09 2006-08-16 株式会社钟根堂 一种泰克利玛的固体分散体
CA2548376A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060940A2 (de) * 2003-11-27 2005-07-07 Bayer Healthcare Ag Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung
WO2006072367A1 (de) * 2004-12-24 2006-07-13 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1957048A2 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822458B2 (en) 1999-12-24 2014-09-02 Bayer Intellectual Property Gmbh Substituted oxazolidinones and their use in the field of blood coagulation
US8530505B2 (en) 1999-12-24 2013-09-10 Bayer Intellectual Property Gmbh Substituted oxazolidinones and their use in the field of blood coagulation
US8129378B2 (en) 1999-12-24 2012-03-06 Bayer Pharma Aktiengesellschaft Substituted oxazolidinones and their use in the field of blood coagulation
US7767702B2 (en) 2001-06-20 2010-08-03 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones for combinational therapy
US8106192B2 (en) 2003-01-07 2012-01-31 Bayer Pharma Aktiengesellschaft Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US9415053B2 (en) 2003-11-27 2016-08-16 Bayer Intellectual Property Gmbh Solid, orally administrable pharmaceutical composition
US9402851B2 (en) 2003-11-27 2016-08-02 Bayer Intellectual Property Gmbh Process for the preparation of a solid, orally administrable pharmaceutical composition
US9539218B2 (en) 2005-01-31 2017-01-10 Bayer Intellectual Property Gmbh Prevention and treatment of thromboembolic disorders
US7932278B2 (en) 2005-09-23 2011-04-26 Bayer Schering Pharma Aktiengesellschaft 2-aminoethoxyacetic acid derivatives and their use
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US8586082B2 (en) 2005-10-04 2013-11-19 Bayer Intellectual Property Gmbh Solid orally administerable pharmaceutical dosage forms with rapid active principle release
WO2010003641A1 (en) 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
JP2011527297A (ja) * 2008-07-08 2011-10-27 ラーツイオフアルム・ゲー・エム・ベー・ハー ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）−フェニル］−１，３−オキサゾリジン−５−イル｝−メチル）−２−チオフェンカルボキサミドを含む医薬組成物
WO2010017948A3 (en) * 2008-08-11 2010-04-29 Ratiopharm Gmbh Pharmaceutical compositions of rivaroxaban with modified release properties
WO2010017948A2 (en) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
WO2010140007A2 (en) * 2009-06-05 2010-12-09 Euro-Celtique S.A. Dosage form
WO2010140007A3 (en) * 2009-06-05 2011-11-17 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
AU2010255502B2 (en) * 2009-06-05 2016-09-22 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
US9814679B2 (en) 2009-06-05 2017-11-14 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug
WO2010146179A3 (en) * 2009-06-18 2011-04-14 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
EA035562B1 (ru) * 2009-06-18 2020-07-08 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения твердой фармацевтической композиции, содержащей ривароксабан
WO2010146179A2 (en) 2009-06-18 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
WO2011042156A1 (en) 2009-10-06 2011-04-14 Ratiopharm Gmbh Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US9266868B2 (en) 2010-07-06 2016-02-23 Sandoz Ag Crystalline form of rivaroxaban dihydrate
WO2012004245A1 (en) 2010-07-06 2012-01-12 Sandoz Ag Crystalline form of rivaroxaban dihydrate
DE102010063127A1 (de) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
WO2012080184A2 (de) 2010-12-15 2012-06-21 Bayer Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10258616B2 (en) 2013-11-13 2019-04-16 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2022199896A1 (en) 2021-03-24 2022-09-29 Pharmathen S.A. Pharmaceutical composition comprising rivaroxaban and method of preparation thereof

Also Published As

Publication number Publication date
DOP2006000209A (es) 2007-04-30
PE20070588A1 (es) 2007-08-17
BRPI0616874A2 (pt) 2011-07-05
CN101321517B (zh) 2012-11-28
JP2009510138A (ja) 2009-03-12
MY143351A (en) 2011-04-29
CR9864A (es) 2008-10-31
JP5147703B2 (ja) 2013-02-20
IL190618A0 (en) 2008-11-03
RU2440119C2 (ru) 2012-01-20
WO2007039122A3 (de) 2007-10-11
CU23808B7 (es) 2012-04-15
CN101321517A (zh) 2008-12-10
UA90545C2 (ru) 2010-05-11
CA2624306A1 (en) 2007-04-12
KR101445398B1 (ko) 2014-09-26
US20100151011A1 (en) 2010-06-17
DE102005047561A1 (de) 2007-04-05
NZ567094A (en) 2011-05-27
CU20080052A7 (es) 2011-04-26
SV2009002857A (es) 2009-01-14
RU2008116831A (ru) 2009-11-10
HK1127284A1 (en) 2009-09-25
CA2624306C (en) 2014-12-09
US8586082B2 (en) 2013-11-19
ECSP088339A (es) 2008-06-30
AU2006299192A1 (en) 2007-04-12
TW200803866A (en) 2008-01-16
UY29835A1 (es) 2007-05-31
GT200600445A (es) 2007-05-08
KR20080067638A (ko) 2008-07-21
TWI389691B (zh) 2013-03-21
AR056564A1 (es) 2007-10-10
ZA200802873B (en) 2009-09-30
AU2006299192B2 (en) 2012-04-19
EP1957048A2 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
WO2007039122A2 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
US11793809B2 (en) Pharmaceutical compositions of nilotinib
EP1689370B2 (de) VERFAHREN ZUR HERSTELLUNG EINER FESTEN, ORAL APPLIZIERBAREN PHARMAZEUTISCHEN ZUSAMMENSETZUNG Mit 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EP1830855B1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
KR101156916B1 (ko) 이마티닙 및 방출 지연제를 포함하는 제약 조성물
EP2355802A1 (de) Intermediate und orale darreichungsformen enthaltend lenalidomid
CN106232144B (zh) 固体分散体
AU2013361307A1 (en) Orally disintegrating tablet formulation for enhanced bioavailability
TW200848056A (en) Solid dispersion of a neurokinin antagonist
EP2595607A2 (de) Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2021107967A1 (en) Pharmaceutical compositions of lurasidone
CA2899389A1 (en) Solid dispersion comprising amorphous cilostazol
JP2021167306A (ja) 崩壊性粒子の製造方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680045548.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2562/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006792199

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 567094

Country of ref document: NZ

Ref document number: 2624306

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008040566

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004470

Country of ref document: MX

Ref document number: 12008500812

Country of ref document: PH

Ref document number: 190618

Country of ref document: IL

Ref document number: CR2008-009864

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2008533890

Country of ref document: JP

Ref document number: 08034001

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006299192

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006299192

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087010702

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008116831

Country of ref document: RU

Ref document number: A20080581

Country of ref document: BY

WWE Wipo information: entry into national phase

Ref document number: 12089148

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006792199

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0616874

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080404